Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - tenecteplase - injection, powder, for solution - tenecteplase 10000 u/vial

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - tenecteplase - myocardial infarction - antithrombotic agents - metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left-bundle-branch block within six hours after the onset of acute-myocardial-infarction symptoms.,

Canada - English - Health Canada

hoffmann-la roche limited - tenecteplase - powder for solution - 50mg - tenecteplase 50mg - thrombolytic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tenecteplase - powder and solvent for solution for injection - 10000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tenecteplase - powder and solvent for solution for injection - 8000unit

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

boehringer ingelheim, germany - tenecteplase - powder and solvent for solution for injection - 10000 iu

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - tenecteplase 50 mg/vial - 50 mg/vial

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - tenecteplase 30mg (recombinant) - powder for injection - 30 mg - active: tenecteplase 30mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - tenecteplase 40mg (recombinant) - powder for injection - 40 mg - active: tenecteplase 40mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - tenecteplase 50mg (recombinant) - powder for injection - 50 mg - active: tenecteplase 50mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.